Before testing a drug on people, researchers must find out whether it has the potential to cause serious harm, this is preclinical development.
The importance of biomarker selection in healthcare
Biomarkers have repeatedly demonstrated their value in healthcare product development over the last decades. From early preclinical development to post-marketing studies, biomarkers significantly increase the success rates of clinical evaluations by up to 20%, reducing the main cost per patient and facilitating regulatory approval. In this whitepaper, learn more about biomarkers' necessity in pharmacological and medical product development, the processes for biomarker selection and identification, and how to overcome some of the major challenges associated with these activities.